Focus: Evofem Biosciences is a women's health-focused biotech company headquartered in San Diego with a commercial-stage portfolio anchored by PHEXXI (contraceptive) and SOLOSEC (anti-infective). The company operates as a focused specialty player in an underserved therapeutic area.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Evofem Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Evofem Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Evofem Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship contraceptive product generating majority of company revenue with 10+ year patent protection remaining.
Secondary anti-infective product with extended LOE horizon, though modest revenue base suggests niche market positioning.
Evofem Reports First Quarter 2026 Financial Results and Provides Business Update - Business Wire
Evofem Reports First Quarter 2026 Financial Results and Provides Business Update Business Wire
Evofem (OTC: EVFM) grants Clovis Davis 5-year exclusive SOLOSEC rights in Africa - Stock Titan
Evofem (OTC: EVFM) grants Clovis Davis 5-year exclusive SOLOSEC rights in Africa Stock Titan
8-K Filing: Evofem Biosciences, Inc. (EVFM) (CIK 0001618835) — EX-99.1
EX-99.1
Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa - Business Wire
Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa Business Wire
Evofem Reports Fifth Consecutive Year of Net Sales Growth - Business Wire
Evofem Reports Fifth Consecutive Year of Net Sales Growth Business Wire
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 6 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo